SCHEMBL21612047

SCHEMBL21612047

FC(F)(F)c1cc(SCc2cnc(-c3ccc(Oc4ccccc4)cc3)s2)ccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARD Q03181 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP3A4 P08684 1/20 0.38
▸ LMNA P02545 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ LTA4H P09960 1/20 0.35
▸ PDE10A Q9Y233 1/20 0.35
▸ ALOX5AP P20292 1/20 0.35
▸ FEN1 P39748 1/20 0.35
▸ GCK P35557 1/20 0.35
▸ S1PR1 P21453 1/20 0.35
▸ LOX P28300 1/20 0.34
▸ LOXL2 Q9Y4K0 1/20 0.34
▸ FAAH O00519 1/20 0.34
▸ HDAC3 O15379 1/20 0.34
▸ HDAC4 P56524 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21611942 0.84 PPARD (0.47) PPARDALDH1A1SMN1; SMN2CYP2C19CYP2C9
SCHEMBL21611925 0.80 CYP3A4 (0.41) SMN1; SMN2CYP2C19CYP3A4LTA4HPDE10A
SCHEMBL21614677 0.80 CYP2C19 (0.60) SMN1; SMN2CYP2C19CYP2C9CYP3A4LTA4H
SCHEMBL21611947 0.75 PPARD (0.40) PPARDALDH1A1SMN1; SMN2LMNATSHR
SCHEMBL21611937 0.75 LOXL2 (0.38) PPARDALDH1A1SMN1; SMN2CYP2C19CYP2C9
SCHEMBL21611938 0.74 LTA4H (0.40) ALDH1A1CYP2C19CYP3A4LTA4HALOX5AP
SCHEMBL30016369 0.73 LOXL2 (0.46) SMN1; SMN2CYP3A4LOXLOXL2
SCHEMBL15454013 0.73 LOXL2 (0.46) SMN1; SMN2CYP3A4LOXLOXL2
SCHEMBL21611934 0.73 CYP3A4 (0.37) CYP2C19CYP2C9CYP3A4PDE10AGCK
SCHEMBL21614668 0.71 CYP3A4 (0.67) CYP2C19CYP3A4HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 PPARD 297/4885ALDH1A1 4593/4885SMN1; SMN2 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback